|

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

RECRUITINGN/ASponsored by University of Chicago
Actively Recruiting
PhaseN/A
SponsorUniversity of Chicago
Started2026-05-19
Est. completion2027-06-15
Eligibility
Age15 Years+
Healthy vol.Accepted
Locations1 site

Summary

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

Eligibility

Age: 15 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age of 15 years or older at time of enrollment
* Diagnosed with ALL or T-cell lymphoblastic lymphoma
* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.

Exclusion Criteria:

* Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
* Patient does not wish to participate
* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

Conditions3

Acute Lymphoblastic LeukemiaCancerT Cell Lymphoblastic Lymphoma

Locations1 site

University of Chicago Medicine Comprehensive Cancer Center
Clinical Trials Intake855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.